Evaluation and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A

被引:13
|
作者
Li Gaofeng [1 ]
Tan Jun [1 ]
Pan Bo [2 ]
Zou Bosheng [1 ]
Zhong Qian [1 ]
Liu Dongping [1 ]
机构
[1] Hunan Normal Univ, Dept Plast & Cosmet Surg, Affiliated Hosp 1, Changsha 410005, Hunan, Peoples R China
[2] Chinese Acad Med Sci, Auricular Reconstruct Ctr, Plast Surg Hosp, Beijing 100037, Peoples R China
来源
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY | 2010年 / 63卷 / 12期
关键词
Botulinum toxin A; Masseter; Facial morphology; Indication; Evaluation; HYPERTROPHY; MUSCLE;
D O I
10.1016/j.bjps.2009.12.019
中图分类号
R61 [外科手术学];
学科分类号
摘要
Few reports exist on effective methods of evaluating the effects and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A. The method for selecting indicative factors, as determined by the change of masseteric area volume at a standard frontal view when tightly clenching teeth, was used in this study. Patients with varying masseteric area volume were randomly enrolled. Bilateral masseteric muscles were treated with multi-point percutaneous intramuscular injections of botulinum toxin type A, 30-50 u for each side. Changes in facial appearance and satisfaction of patients were observed and standard frontal view photographs were taken pre-treatment and 2-3 months post-treatment. Following this, the anterior facial height(FH), bizygomatic facial width (FWz) and intergonial width (FWg) were measured from the photographs. The indices of FH/FWz and FWg/FWz were calculated and analysed. The results showed that the volume of masseteric area was reduced and the facial morphology was improved at 2-4 weeks post-injection, with maximum reduction at 2-3 months post-injection. All of the 32 patients were satisfied with the clinical effects. The pre-treatment and post-treatment values of FH/FWz were 0.8309 +/- 0.0423 and 0.8331 +/- 0.0382, respectively, and FWg/FWz values were 0.8281 +/- 0.0209 and 0.7925 +/- 0.0206 (P < 0.01), respectively. In conclusion, the appropriateness of masseteric injection of botulinum toxin type A for improving facial morphology can be determined by the changes in masseteric area volume at a standard frontal view of tightly clenched teeth. In addition, the facial index of FWg/FWz can be used to evaluate the treatment. (C) 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:2026 / 2031
页数:6
相关论文
共 50 条
  • [31] Paradoxical masseteric bulging after botulinum neurotoxin type A injection
    Sandhu, Shaiba
    Shaefer, Jeffry
    BMJ CASE REPORTS, 2024, 17 (05)
  • [32] Botulinum toxin type A in headache treatment. Established and experimental indications
    Gaul, C.
    Holle-Lee, D.
    Straube, A.
    NERVENARZT, 2016, 87 (08): : 853 - 859
  • [33] The use of Botulinum toxin-A injection for facial wrinkles: a histological and immunohistochemical evaluation
    El-Domyati, Moetaz
    Attia, Sameh K.
    El-Sawy, Ashraf E.
    Moftah, Noha H.
    Nasif, Ghada A.
    Medhat, Walid
    Marwan, Belkais
    JOURNAL OF COSMETIC DERMATOLOGY, 2015, 14 (02) : 140 - 144
  • [34] Botulinum Toxin Application in Facial Esthetics and Recent Treatment Indications (2013-2018)
    Kattimani, Vivekanand
    Tiwari, Rahul Vinay Chandra
    Gufran, Khalid
    Wasan, Bharti
    Shilpa, P. H.
    Khader, Anas Abdul
    JOURNAL OF INTERNATIONAL SOCIETY OF PREVENTIVE AND COMMUNITY DENTISTRY, 2019, 9 (02): : 99 - 105
  • [35] Botulinum Toxin in the Treatment of Facial Paralysis
    Mehdizadeh, Omid B.
    Diels, Jacqueline
    White, William Matthew
    FACIAL PLASTIC SURGERY CLINICS OF NORTH AMERICA, 2016, 24 (01) : 11 - +
  • [36] Botulinum toxin for the treatment of facial flushing
    Yuraitis, M
    Jacob, CI
    DERMATOLOGIC SURGERY, 2004, 30 (01) : 102 - 104
  • [37] Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy
    Armstrong, MWJ
    Mountain, RE
    Murray, JAM
    CLINICAL OTOLARYNGOLOGY, 1996, 21 (01): : 15 - 20
  • [38] Botulinum toxin type A.: Indications and results
    Póo, P
    López-Casas, J
    Galván-Manso, M
    Aquino-Fariña, L
    Terricabras-Carol, L
    Campistol, J
    REVISTA DE NEUROLOGIA, 2003, 37 (01) : 74 - 80
  • [39] BOTULINUM TOXIN TYPE A: EXPLORING NEW INDICATIONS
    Brashear, A.
    DRUGS OF TODAY, 2010, 46 (09) : 671 - 682
  • [40] THE MEDICAL-MANAGEMENT OF MASSETERIC HYPERTROPHY WITH BOTULINUM TOXIN TYPE-A
    MOORE, AP
    WOOD, GD
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 1994, 32 (01): : 26 - 28